Negative symptoms in schizophrenia are associated with decreased dopaminergic activity in the prefrontal cortex (PFC). It is hypothesized that increasing dopamine levels would alleviate negative symptoms. Termination of dopamine activity in the PFC is mainly via catechol-O-methyl tranferase (COMT) activity. Hence, inhibition of COMT activity with entacapone should reverse PFC dopaminergic transmission. To assess the efficacy of entacapone addition to antipsychotic treatment in patients with residual schizophrenia, we conducted a double-blind, randomised, placebo-controlled study for 12 wk of treatment with entacapone or placebo. Clinical measures (PANSS, CGI and QLS) were obtained at baseline and at weeks 4, 8 and 12 and cognitive functions were assessed by the RBANSS. Significant improvement over time in PANSS and QLS scores was observed in both groups. However, entacapone did not demonstrate a beneficial effect compared to placebo. Therefore, this study does not support a therapeutic role for entacapone in residual schizophrenia.
Introduction
Negative symptoms in schizophrenia have been suggested to be associated with reduced dopamine activity in the frontal cortex (Goto and O'Donnell, 2004; Guillin et al., 2007) , and thus may be alleviated by selective elevation of dopamine efficacy in the frontal cortex. Catechol-o-methyl transferase (COMT), the postsynaptic enzyme that methylates released dopamine to its final metabolite, homovanillic acid, has been suggested as a candidate for selective modulation of dopamine activity in the prefrontal cortex (PFC) (Weinberger et al., 2001) . Findings in animals indicate that in the striatum dopamine synaptic action is terminated primarily by transporter-mediated reuptake into the presynaptic terminals (Giros et al., 1996) , while COMT effect is marginal (Gainetdinov et al., 1998) . In contrast, in the PFC, COMT has been implicated as a key player in the regulation of extracellular dopamine concentration. Furthermore, both pharmacological and genetic manipulation leading to COMT deficiency or reduced activity resulted in increased dopamine turnover and improved performance on memory tasks (Karoum et al., 1994; Gasparini et al., 1997; Liljequist et al., 1997; Gogos et al., 1998; Sesack et al., 1998) . COMT exhibits a functional polymorphism (Val 158 Met allele) affecting its enzyme activity (Val-COMT has 3-4-fold greater enzyme activity than Met-COMT) (Lachman et al., 1996) . This polymorphism has been linked to both the risk and severity of schizophrenia (Weinberger et al., 2001; Norton et al., 2002; Park et al., 2002; Glatt et al., 2003) , thus supporting the potential benefit of employing COMT inhibitors as an augmentation strategy for treating negative symptoms in schizophrenia. The objective of this study was to investigate, in a double-blind controlled design, the benefit of adding the COMT inhibitor entacapone, which is used for the treatment of Parkinson's disease, to ongoing antipsychotic treatment in patients with residual schizophrenia and significant negative symptoms.
Subjects and method

Patients
Fifty stable schizophrenic patients (DSM IV criteria), age 18-55, with predominantly negative symptoms, were enrolled after providing written informed consent to participate in the study, which was approved by the local ethical review board (NIH registration NCT00192855).
All patients were evaluated by the Mini-international neuropsychiatric interview and Positive and Negative Syndrome Scale (PANSS), followed by a physical examination, ECG and laboratory screening to exclude any pathological physical condition. Inclusion criteria were: DSM-IV diagnosis of schizophrenia, total PANSS score 565, negative symptoms sub-scale scores 520 and a fixed maintenance dose of current antipsychotic treatment during the last 8 weeks.
Two weeks after initial assessment, the PANSS was re-administered, to evaluate the stability of the patient's mental state (study baseline assessment). Patients who had a change of PANSS in either the total score or the negative score higher than 15% were excluded from the study.
Additional exclusion criteria were: evidence of marked affective symptoms, history or findings of organic brain damage, current or recent alcohol or drug abuse and uncontrolled medical condition.
Treatment
Patients were randomized to receive from day one of the study, either entacapone 600 mg BID or matching placebo (using a computer generated randomization list), in addition to their ongoing antipsychotic treatment. After completion of the trial, entacapone was tapered gradually over one week under clinical supervision. Entacapone was purchased from Novartis, and matching placebo was prepared locally.
Clinical and cognitive assessments
Patients were assessed at baseline, and weeks 4, 8 and 12, using the following rating scales: Clinical Global Impression (CGI), Positive and Negative Symptom scale (PANSS), Quality of Life Scale (QLS) and Treatment Emergent Symptoms Scale (TESS). Assessment of clinical ratings, for all patients, was performed by the same board-certified psychiatrist (HK) who had previous extensive experience with these scales. Assessment of cognitive functions was done at baseline and at week twelve (study end-point) using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS was administered by two Masters level psychology students with previous training in this battery. Patients were instructed not to report urine colour change, if they had no additional urinary complaints, in order to maintain the 'blindness' of the examining psychiatrist.
Data analysis
The Student's t-test or chi-square was used to compare the demographic and clinical characteristics of the two groups. In order to examine the effect of entacapone augmentation, repeated measure analysis of variance (MANOVA) was used. The dependent variables were the post-treatment scores at the various time-points of the rating scales. The independent variables were time (within-subject factor) and treatment group (betweensubject factor).
Results
Twenty-five patients received entacapone and 25 received placebo. The two groups did not differ in demographic and clinical characteristics (Table 1) .
Five patients dropped out from the study, 3 from the placebo group and 2 from the entacapone group. Four of these patients dropped out during the first week due to gastrointestinal complaints and malaise, one additional patient dropped out after six weeks of entacapone, due to clinical deterioration requiring hospitalisation. One additional patient reported diarrhoea but completed the study. No other serious adverse effects were observed. Both groups exhibited significant improvement over time on the PANSS and QLS rating scales, with no apparent difference between the groups (Table 2a, b) . No time effect and no between-group differences were observed in the CGI scores and in the cognitive functions, as assessed by the RBANS (Table 2a, b) .
Discussion
This randomised controlled double-blind study was designed to evaluate the ability of entacapone to alleviate negative symptoms and cognitive impairments in patients with schizophrenia. Entacapone was found to be safe and well tolerated with no significant adverse effects compared to placebo. However, entacapone was not found to be superior compared to placebo in any of the clinical measures, as shown by the lack of group and time interaction effects in the PANSS and QLS (Table 2a, b) . The significant time-effect in both treatment groups suggests that the research setting in itself had a beneficial effect. This effect is exhibited in the positive and negative symptoms (p<0.01 in all subscales, Table 2a, b). Interestingly, we reported similar findings in a previous study, which assessed the potential benefit of deprenyl augmentation to ongoing antipsychotic treatment in patients with residual schizophrenia (Jungerman et al., 1999) .
The cognitive functions, as evaluated by the RBANS, did not show any improvement over time in either group, implying that unlike clinical measures, cognitive functioning was not affected by the study setting per se.
In order to address the possibility of a type-II error, namely, the possibility that our sample size was too small to reveal the beneficial effect of entacapone, we calculated the number of subjects required to demonstrate a significant beneficial effect for entacapone. This calculation revealed that 400 patients would have been required in order to show a beneficial entacapone effect in the PANSS positive or general subscales (power level of 0.9), and more than 900 patients in the negative and total PANSS. These numbers suggest that the likelihood for a type-II error is very low.
While our results do not support the potential utility of entacapone as augmentation therapy in schizophrenia, this does not rule out the possibility that COMT inhibition, as a treatment strategy, might be beneficial in schizophrenia. It is well known that the blood-brainbarrier (BBB) penetrance of entacapone is relatively low (Kaakkola and Wurtman, 1992; Nissinen et al., 1992; Ishikawa et al., 1996; Brannan et al., 1997) . This characteristic does not interfere with entacapone efficacy in the treatment of Parkinson's disease, where a peripheral inhibition of L-DOPA degradation is required. However, in the case of schizophrenia, where a central effect on dopamine degradation is required, the low penetrance of entacapone through the BBB might interfere with its efficacy. Thus, COMT inhibitors with higher penetrance through the BBB might be more efficacious. Entacapone augmentation in schizophrenic patients 339
In conclusion, the results of our study do not support a clinically useful effect size of entacapone in the treatment of negative symptoms in schizophrenia, and thus, do not support the clinical benefit of entacapone augmentation. However, the positive effect of the treatment setting, which involves more intensive patient-doctor contact, may suggest that a clinical routine involving more intense therapeutic contact might positively affect the clinical status of these patients.
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